Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist

被引:95
作者
McCurdy, CR
Sufka, KJ
Smith, GH
Warnick, JE
Nieto, MJ
机构
[1] Univ Mississippi, Sch Pharm, Dept Med Chem, University, MS 38677 USA
[2] Univ Mississippi, Sch Pharm, Dept Psychol, University, MS 38677 USA
[3] Univ Mississippi, Sch Pharm, Dept Pharmacol, University, MS 38677 USA
[4] Univ Mississippi, Sch Pharm, Pharmaceut Sci Res Inst, University, MS 38677 USA
关键词
salvinorin A; kappa opioid receptor agonist; tail-flick; hotplate; acetic acid writhing; mouse; antinociception;
D O I
10.1016/j.pbb.2005.12.011
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Salvinorin A, is a structurally unique, non-nitrogenous, kappa opioid receptor (KOP) agonist. Given the role of KOPs in analgesic processes, we set out to determine whether salvinorin A has antinociceptive activity in thermal and chemo-nociceptive assays. The tail-flick assay was employed to investigate 1) salvinorin A's (0.5, 1.0, 2.0, and 4.0 mg/kg) dose-response and time-course (10, 20, and 30 min) effects in a thermal nociceptive assay, and 2) the ability for the KOP antagonist norBNI (10.0 mg/kg) to prevent salvinorin A antinociception. The hotplate assay was utilized as a second thermal nociceptive measure to test salvinorin A's dose-response effects. The acetic acid abdominal constriction assay was used to study salvinorin A's dose-response and time-course (over 30 min) effects in a chemo-nociceptive assay. Together, these studies revealed that salvinorin A produces a dose-dependent antinociception that peaked at 10 min post-injection but rapidly returned to baseline. Additionally, pretreatment with the KOP antagonist norbinaltorphimine (norBNI) reversed salvinorin A-induced antinociception. These findings demonstrate that salvinorin A produces a KOP mediated antinociceptive effect with a short duration of action. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:109 / 113
页数:5
相关论文
共 27 条
[1]   Analgesic and antiinflammatory effects of two novel κ-opioid peptides [J].
Binder, W ;
Machelska, H ;
Mousa, S ;
Schmitt, T ;
Rivière, PJM ;
Junien, JL ;
Stein, C ;
Schäfer, M .
ANESTHESIOLOGY, 2001, 94 (06) :1034-1044
[2]  
Bodnar R J, 1998, Expert Opin Investig Drugs, V7, P485, DOI 10.1517/13543784.7.4.485
[3]   The plant-derived hallucinogen, salvinorin A, produces κ-opioid agonist-like discriminative effects in rhesus monkeys [J].
Butelman, ER ;
Harris, TJ ;
Kreek, MJ .
PSYCHOPHARMACOLOGY, 2004, 172 (02) :220-224
[4]   Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist:: Structural and functional considerations [J].
Chavkin, C ;
Sud, S ;
Jin, WZ ;
Stewart, J ;
Zjawiony, JK ;
Siebert, DJ ;
Toth, BA ;
Hufeisen, SJ ;
Roth, BL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03) :1197-1203
[5]   Pharmacology and clinical experience with fedotozine [J].
Delvaux, M .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (01) :97-110
[6]  
ENDOH T, 1992, ARCH INT PHARMACOD T, V316, P30
[7]   Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse [J].
Fantegrossi, WE ;
Kugle, KM ;
Valdes, LJ ;
Koreeda, M ;
Woods, JH .
BEHAVIOURAL PHARMACOLOGY, 2005, 16 (08) :627-633
[8]   ROLE OF DIURNAL-VARIATION AND RECEPTOR SPECIFICITY IN THE OPIOIDERGIC REGULATION OF FOOD-INTAKE IN FREE-FED AND FOOD-DEPRIVED RATS [J].
GULATI, K ;
RAY, A ;
SHARMA, KK .
PHYSIOLOGY & BEHAVIOR, 1991, 49 (06) :1065-1071
[9]   Antidepressant effects of the herb salvia divinorum: A case report [J].
Hanes, KR .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (06) :634-635
[10]   Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands [J].
Harding, WW ;
Tidgewell, K ;
Byrd, N ;
Cobb, H ;
Dersch, CM ;
Butelman, ER ;
Rothman, RB ;
Prisinzano, TE .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :4765-4771